Short answer: To start a peptide telehealth business, you build the brand and patient experience while licensed providers evaluate each patient and prescribe only through legitimate pathways: FDA-approved products or compounded preparations from licensed pharmacies that meet federal bulk drug substance rules. Research-use-only peptides are not for human use and must never be sold to patients. FDA’s peptide rules shifted in 2026, so confirm each product with counsel.
If you want to start a peptide telehealth business, you are entering one of the fastest-moving regulatory areas in digital health. Peptides are being recategorized, advisory committees are voting, and FDA has been sending warning letters to sellers who market peptides for human use outside legitimate channels. The whitespace is real, but so is the risk. The peptide brands that last will be the ones that run like a real digital clinic, the ones that know exactly which products they can offer, through which pathway, and why.
WellieMD’s founder, Jessica Lynne White, BS, MSPT, spent 27 years as a licensed physical therapist, and her own brands, KIN Meds, PauseRx, Octane Rx and Naked Rx, run on WellieMD. This guide is the founder-level playbook: how FDA regulates compounded peptides, what changed in 2026, why research-use-only products are off limits, and the business steps to launch responsibly.
Three kinds of peptide products, and only two belong in a clinic
“Peptide” describes a chemical structure, not a legal category. For a founder, what matters is the regulatory pathway a product comes through.
| Product type | What it is | Belongs in a telehealth clinic? |
|---|---|---|
| FDA-approved peptide drugs | Products approved by FDA and dispensed by licensed pharmacies with a valid prescription | Yes, when a licensed provider determines the product is appropriate |
| Compounded peptide preparations | Patient-specific preparations from licensed pharmacies, made from bulk substances that meet federal requirements | Only when the specific substance is eligible for compounding and a licensed provider prescribes it for an individual patient |
| Research-use-only (RUO) peptides | Chemicals sold for laboratory research, not for human use | No. Never sell, recommend or route patients to RUO products |
How FDA regulates compounded peptides
The 503A bulk drug substance rules
Under section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacy compounding from a bulk drug substance generally must use a substance that meets one of three criteria: it complies with an applicable USP or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on FDA’s 503A bulks list. Many popular peptides meet none of those criteria, which is why their status depends on FDA’s nomination process.
FDA’s interim categories
While FDA evaluates nominated substances, it sorts them into interim categories. Category 1 covers substances under evaluation, where FDA has said it does not intend to take action against compounders who meet certain conditions. Category 2 covers substances FDA has identified as raising significant safety risks. Category 3 covers substances nominated without adequate support. FDA’s page on 503A bulk drug substances, updated in May 2026, also says FDA does not intend to place substances nominated on or after January 7, 2025 into these categories. These categories are interim policy, not approval, and they can change.
503B outsourcing facilities
503B outsourcing facilities follow a separate framework, with a separate bulks list based on clinical need. Do not assume a substance that a 503A pharmacy can use is also available from a 503B facility, or the reverse. Ask each pharmacy partner for the legal basis for every product it prepares for your patients.
Which peptides FDA flagged, and what changed in 2026
In 2023, FDA placed a group of popular peptides, including BPC-157, into category 2, citing concerns such as immunogenicity, peptide-related impurities and limited human safety data. In 2026, the picture changed in several ways. Based on the FDA documents we reviewed in September 2026:
| Substance or group | Status in FDA documents we reviewed | What it means for a founder |
|---|---|---|
| BPC-157, TB-500 (thymosin beta-4 fragment), KPV, MOTs-C, Epitalon, Semax, CJC-1295, AOD-9604, Melanotan II and others | Listed by FDA as previously in category 2 with nominations withdrawn | Withdrawal from category 2 is not the same as approval for compounding. These substances were not on the 503A bulks list in the documents we reviewed. |
| BPC-157, KPV, TB-500, MOTs-C, Epitalon and Semax | FDA’s Pharmacy Compounding Advisory Committee voted in favor of adding them to the 503A bulks list at its July 23 and 24, 2026 meeting | Advisory votes are recommendations. FDA is not bound by them, and adding a substance to the bulks list requires rulemaking. We did not find a final rule as of this writing. |
| Ibutamoren mesylate and Kisspeptin-10 | Category 2 on FDA’s list updated May 14, 2026 | FDA has identified significant safety risks. Do not offer. |
| GHRP-2 and GHRP-6 | Category 3 on FDA’s list updated May 14, 2026 | Nominated without adequate support. Not eligible for category 1 treatment. |
| GHK-Cu (except injectable routes) | Category 1 on FDA’s list updated May 14, 2026, with a planned advisory committee consultation before the end of February 2027 | Route matters. Injectable GHK-Cu is not covered by that listing. |
This area is changing month to month. A substance that is off limits today could become eligible after rulemaking, and a substance in category 1 today could move. Before you list any peptide, have a healthcare attorney and your pharmacy partner confirm its current status in writing, and recheck it on a regular schedule.
Research-use-only products are never for patients
RUO peptides are sold as laboratory chemicals. They are not made or labeled for human use, and they have no place in a telehealth business. FDA’s 2026 warning letters to online peptide sellers show how the agency views them: a “research use only” or “not for human consumption” disclaimer does not protect a seller when the surrounding marketing, such as therapeutic claims, dosing information or the sale of reconstitution supplies, shows the products are intended for people. FDA treated those products as unapproved new drugs.
For a telehealth founder, the rule is simple. Never source, sell, recommend, link to or “wink at” RUO products. Never let affiliates, influencers or support scripts point patients toward them. Every product a patient receives should come through a licensed pharmacy with a valid prescription from a licensed provider.
Sermorelin and NAD+
Sermorelin
Sermorelin acetate was once an FDA-approved product sold as Geref. The manufacturer discontinued it, and FDA withdrew the approvals effective June 18, 2009. In 2013, FDA published a determination in the Federal Register that the Geref products were not withdrawn from sale for reasons of safety or effectiveness. Sermorelin did not appear in FDA’s May 2026 interim category lists that we reviewed. Its compounding status depends on the pharmacy’s legal basis for preparing it, so ask your pharmacy partner to explain that basis and have counsel confirm it. There is no currently marketed FDA-approved sermorelin product that we identified.
NAD+
Nicotinamide adenine dinucleotide (NAD) appeared in category 1, substances under evaluation, on FDA’s 503A list updated May 14, 2026. Category 1 means FDA has said it does not intend to take action against compounders who meet the interim policy’s conditions while it evaluates the substance. It does not mean NAD+ is FDA-approved, and category status can change. Describe NAD+ accurately and avoid health claims.
Screening and provider evaluation
Every peptide prescription should start with an individualized evaluation by a provider who is licensed or legally permitted to practice in the patient’s state. Your intake should collect health history, medications, allergies, pregnancy status and goals in plain language, and it should give providers a way to request labs or decline a request. Many peptides have limited human safety data, which is one reason FDA flagged them in the first place. That makes careful screening and honest patient education even more important.
Marketing a peptide brand responsibly
- No health outcome claims. Do not promise healing, recovery, longevity, fat loss or performance.
- Never call compounded peptides FDA-approved. Say clearly that compounded medications are not FDA-approved.
- No “FDA-approved pharmacy” language. FDA does not approve or license pharmacies.
- No RUO references. Do not mention, compare or link to research-use-only products anywhere.
- Keep claims substantiated. The FTC expects adequate substantiation for objective health claims before an ad runs.
- Plan for LegitScript. Major ad platforms and card networks recognize LegitScript Healthcare Certification.
How to start a peptide telehealth business: step by step
- Get legal guidance on your formulary. Work with a healthcare attorney on entity structure and on the status of every product you plan to offer. Our guide on how to start a telehealth business without being a doctor covers the ownership basics.
- Build your product list from pathways, not trends. Start with FDA-approved products and compounded preparations that counsel confirms are eligible.
- Vet pharmacy partners. Ask each licensed pharmacy for its legal basis for each product, its sourcing, its testing and its shipping practices.
- Secure licensed provider coverage. Confirm which states you can serve and that providers are comfortable with each product on your list.
- Design a thoughtful intake. Capture history, medications, allergies, pregnancy status and goals.
- Set a recheck schedule. Review the regulatory status of every product on a regular cadence, since peptide rules are moving quickly.
- Budget realistically. See How Much Does It Cost to Start a Telehealth Business? for the categories to plan for.
- Start merchant processing and LegitScript early. Peptide programs often draw extra review.
- Review every claim before it goes live. Check your site, ads, emails and affiliate content.
- Test the full patient journey, then launch. Run test orders from intake to delivery before real patients arrive.
How WellieMD helps
WellieMD is a white-label telehealth platform, also called a digital clinic platform, that connects your peptide brand to licensed providers, licensed 503A compounding pharmacies and brand-name pharmacy pathways. It supports branded intake, licensed provider review, e-prescribing, subscriptions, refills and lab workflows in one place. WellieMD works only with prescription pathways through licensed pharmacies, never research-use-only products. All clinical decisions stay with licensed providers, and product eligibility should be confirmed with your own counsel.
Visit the white-label telehealth platform page for the full platform view. If you want a done-for-you team to build your brand and website, GrowPro has launched 80+ telehealth brands. We build it with you.
Frequently asked questions
Is BPC-157 legal to compound now?
Not clearly. FDA lists BPC-157 as previously in category 2 with its nomination withdrawn, and an FDA advisory committee voted in July 2026 in favor of adding it to the 503A bulks list. Advisory votes are not final, and adding a substance requires rulemaking. Confirm current status with a healthcare attorney before offering it.
Can I sell research-use-only peptides to patients?
No. Research-use-only products are not for human use. FDA has issued warning letters to sellers whose marketing showed human-use intent despite RUO disclaimers. Every product a patient receives should come through a licensed pharmacy with a valid prescription.
Are compounded peptides FDA-approved?
No. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are marketed. Interim category 1 status is also not approval. Your marketing must be accurate about this.
Is sermorelin FDA-approved?
Sermorelin was previously approved as Geref, which was discontinued. FDA withdrew the approvals in 2009 and determined in 2013 that they were not withdrawn for safety or effectiveness reasons. We did not identify a currently marketed FDA-approved sermorelin product. Ask your pharmacy and counsel about its compounding basis.
What is the status of NAD+?
As of FDA’s list updated May 14, 2026, NAD was in category 1, substances under evaluation for the 503A bulks list. That is interim policy, not approval, and it can change. Describe NAD+ accurately and avoid health claims.
Your next step toward a peptide digital clinic
When you start a peptide telehealth business on licensed providers, licensed pharmacies, a formulary your counsel has confirmed and marketing with no outcome claims, you build a digital clinic that can adapt as the rules change. Recheck your product list often, because this category will keep moving. If you are ready to map out your peptide brand, book a demo with WellieMD and we will walk through it together.
This guide is general information, not legal or medical advice. Prescription products require evaluation by a licensed provider. Compounded medications are not FDA-approved.
Sources
- U.S. Food and Drug Administration: Bulk drug substances used in compounding under section 503A of the FD&C Act
- U.S. Food and Drug Administration: Bulk drug substances nominated for use in compounding under section 503A, categories 1, 2 and 3 (updated May 14, 2026)
- U.S. Food and Drug Administration: Certain bulk drug substances for use in compounding that may present significant safety risks
- U.S. Food and Drug Administration: July 23 and 24, 2026 meeting of the Pharmacy Compounding Advisory Committee
- U.S. Food and Drug Administration: Warning letter to an online peptide seller (March 31, 2026)
- Federal Register: Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness (2013)
- U.S. Food and Drug Administration: FDA to telehealth companies, what to know when promoting compounded drugs